Xu Shiyue, Qiu Yumin, Tao Jun
Department of Hypertension and Vascular Disease, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China.
Department of Biomedical Engineering, Molecular Cardiology Program, School of Medicine and School of Engineering, University of Alabama at Birmingham Birmingham United States.
J Transl Int Med. 2021 Dec 31;9(4):234-238. doi: 10.2478/jtim-2021-0017. eCollection 2021 Dec 1.
With the hope of achieving real cardiovascular repair, cell-based therapy raised as a promising strategy for the treatment of cardiovascular disease (CVD) in the past two decades. Various types of cells have been studied for their reparative potential for CVD in the ensuing years. Despite the exciting results from animal experiments, the outcome of clinical trials is unsatisfactory and the development of cell-based therapy for CVD has hit a plateau nowadays. Thus, it is important to summarize the obstacles we are facing in this field in order to explore possible solutions for optimizing cell-based therapy and achieving real clinical application.
怀着实现真正心血管修复的希望，在过去二十年中，基于细胞的疗法作为一种治疗心血管疾病（CVD）的有前景的策略应运而生。在随后的几年里，人们对各种类型的细胞进行了研究，以探讨它们对CVD的修复潜力。尽管动物实验取得了令人兴奋的结果，但临床试验的结果并不理想，如今基于细胞的CVD治疗发展已陷入停滞。因此，总结我们在该领域面临的障碍很重要，以便探索优化基于细胞的疗法并实现真正临床应用的可能解决方案。
